A Study of TQB2102 for Injection in the Treatment of HER2-positive Biliary Tract Cancer

Official title

A Study to Evaluate the Efficacy, Safety, and Immunogenicity of TQB2102 for Injection in the Treatment of HER2-positive Locally Advanced or Metastatic Biliary Tract Cancer

Overview

To evaluate the efficacy and safety TQB2102 for injection in the treatment of patients with Her2-positive biliary tract cancer.

Interventions

• Drug TQB2102 for injection
  TQB2102 for injection is a HER2 dual-antibody-drug Conjugate (ADC)

Primary outcome measures

• Incidence and severity of adverse events (AE) and serious adverse events (SAE) [Time frame: From the time the subject signed the informed consent until 28 days after the last dose/start of the new antitumor therapy]
• Phase II Recommended Dose (RP2D) [Time frame: Baseline up to 24 weeks]

Secondary outcome measures (5)

• Objective response rate (ORR) [Time frame: Baseline up to 36 weeks]
• Progression-free survival (PFS) [Time frame: Baseline up to 36 weeks]
• Disease control rate (DCR) [Time frame: Baseline up to 36 weeks]
• Disease response time (DOR) [Time frame: Baseline up to 36 weeks]
• Overall survival (OS) [Time frame: Baseline up to 36 weeks]

Eligibility criteria

Inclusion criteria

• 18 years ≤ age ≤75 years; Eastern Cooperative Oncology Group (ECOG) score 0 to 1;
• Subjects must provide sufficient tumor tissue sample and confirm HER2 positivity by central laboratory prior to first dose, defined as immunohistochemistry (IHC) 3+ or IHC 2+ with in situ hybridization (ISH) positive;
• The main organs function well;
• Meet the criteria for advanced biliary tract cancer:

• Biliary tract carcinoma confirmed by histology or cytology;
• Non-operable locally advanced, recurrent and/or metastatic disease with at least one measurable lesion according to Evaluation criteria for the efficacy of solid tumors (RECIST) 1.1 criteria;
• Failure of 1-2 prior lines of systemic therapy
• Women of reproductive age should agree that effective contraception must be used during the study period and for 6 months after the end of the study, and that serum or urine pregnancy tests are negative within 7 days prior to study enrollment; Men should agree that effective birth control must be used during the study period and for 6 months after the end of the study period;
• The subjects voluntarily joined the study, signed the informed consent, and the compliance was good.

Exclusion criteria

• Complicated diseases and medical history:

• Have had or are currently suffering from other malignant tumors within 3 years before the first medication;
• Unmitigated toxic effects higher than grade 1 of Common Terminology Criteria for Adverse Events (CTCAE) due to any previous treatment;
• Major surgical treatment, significant traumatic injury, or long-term unhealed wounds or fractures have been received within 4 weeks prior to initial medication;
• Patients with any bleeding or bleeding events ≥CTCAE grade 3 within 4 weeks before the first dose; Aortic/venous thrombosis events, such as cerebrovascular accidents (including transient ischemic attacks), deep vein thrombosis, and pulmonary embolism, occurred within 6 months prior to initial administration; Treatment with low molecular weight heparin was permitted and antiplatelet drugs were prohibited throughout the study period;
• Active viral hepatitis with poor control;
• There is a history of active tuberculosis, idiopathic pulmonary fibrosis, institutional pneumonia, drug-induced pneumonia, radiation pneumonia requiring treatment or active pneumonia with clinical symptoms;
• Have a history of psychotropic drug abuse and can not quit or have mental disorders;
• People who are ready to undergo or have previously received allogeneic bone marrow transplantation or solid organ transplantation;
• Have a history of hepatic encephalopathy;
• Currently on or recently used (within 7 days before the start of study treatment) aspirin (>325 mg/ day (maximum antiplatelet dose) or dipyridamole, ticlopidine, clopidogrel, and cilostazol;
• Subjects with any severe and/or uncontrolled disease.
• Tumor related and treatment:

• For subjects who have received chemotherapy, immunotherapy within 3 weeks before the first dose, radiation therapy or small molecule targeted drugs within 2 weeks, or who are still within the 5 half-lives of the drug (as the shortest time of occurrence), the washout period is calculated from the end time of the last treatment;
• Within 2 weeks before the first use of the drug, the treatment of Chinese patent drugs with anti-tumor indications specified in the National Medical Products Administration (NMPA) approved drug instructions;
• Imaging including computed tomography (CT) or magnetic resonance imaging (MRI) shows that the tumor has invaded important blood vessels, or the investigator determines that the tumor is highly likely to invade important blood vessels during the follow-up study period and cause fatal massive bleeding;
• Uncontrolled pleural effusion, pericardial effusion or moderate to severe ascites that still require repeated drainage;
• Obvious biliary obstruction (except for total bilirubin ≤ 2× upper limit of normal (ULN) after endoscopic stent placement and percutaneous transhepatic biliary drainage);
• Known spinal cord compression, cancerous meningitis, with symptoms of brain metastases, or symptoms controlled for less than 4 weeks.
• Research treatment related:

• Known allergy to study drug excipients;
• Have previously received anti-HER2 therapy drugs (only for the second stage, the first stage is not limited);
• Patients who require immunosuppressive, systemic, or absorbable topical hormone therapy for immunosuppressive purposes and who continue to use it for 7 days prior to initial administration (except for corticosteroids <10 mg per day of prednisone or other therapeutic hormones).
• Participants who participated in and used other anti-tumor clinical trials within 4 weeks before the first medication.
• According to the judgment of the researcher, there is a situation that seriously endangers the safety of the subjects or affects the completion of the study.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation

N/A

Model

Single group

Masking

Open label

Primary purpose

Treatment

Study locations

China · 43 centers

• Fuyang Cancer Hospital — Fuyang
• Anhui Second People's Hospital — Hefei
• Anhui Provincial Cancer Hospital — Hefei
• Cancer Hospital Chinese Academy of Medical Science — Beijing
• Beijing Cancer Hospital — Beijing
• Tsinghua Changgeng Hospital, Beijing — Beijing
• First Affiliated Hospital of Chongqing Medical University — Chongqing
• Fujian Provincial Cancer Hospital — Fuzhou
• … and 35 more centers

Identifiers

NCT: NCT06431490 · TQB2102-Ib/II-01

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗